peplexicon
Choose your depth

Context, anatomy, and key evidence

← Peptide library

anti-aging protein

Klotho

Published evidence · coverage incomplete
Anatomical contextAnatomy connections are not mapped yet.

No body region is highlighted until this profile has a supported anatomical connection. This does not mean the peptide has no biological effects.

Read published mechanism findings ↓

At a glance

What is it—and why does it matter?

An introduction is not yet available. The findings below address specific research questions, not a complete account of this peptide.

This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.

What is it?

A molecule, not a product name.

Identity

In the FGF/FGFR pathway, Klotho functions as a co-receptor alongside fibroblast growth factors (FGFs) and FGF receptors (FGFRs).

Sources[1]pubmedAdvances in FGF/FGFR Signaling: Implications for Disease and Therapy.The fibroblast growth factor (FGF)/FGF receptor (FGFR) signaling, primarily comprising FGFs, FGFRs, and the co-receptor Klotho, regulates key physiological processes, including embryogenesis, tissue homeostasis, metabolism, and neurodevelopment.
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “The fibroblast growth factor (FGF)/FGF receptor (FGFR) signaling, primarily comprising FGFs, FGFRs, and the co-receptor Klotho, regulates key physiological processes, including embryogenesis, tissue homeostasis, metabolism, and neurodevelopment.”

    Advances in FGF/FGFR Signaling: Implications for Disease and Therapy. · Abstract

    pubmed:42633326:605553ad7b0b:605553ad7b0b

How does it work?

Target, response, and disposition.

Mechanism

Klotho (the co-receptor for FGF23) was quantified in blood in a prospective hospitalized COVID-19 cohort to evaluate statistical associations with AKI and longer-term survival (28 months).

Sources[2]pubmedElevated circulating fibroblast growth factor 23 is associated with acute kidney injury and mortality in coronavirus disease 2019 (COVID-19).In this prospective cohort of 111 COVID-19 patients hospitalized at the Indiana University Academic Health Center (April-October 2020), circulating FGF23 and its co-receptor Klotho levels were assessed for association with AKI and 28-month survival.
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “In this prospective cohort of 111 COVID-19 patients hospitalized at the Indiana University Academic Health Center (April-October 2020), circulating FGF23 and its co-receptor Klotho levels were assessed for association with AKI and 28-month survival.”

    Elevated circulating fibroblast growth factor 23 is associated with acute kidney injury and mortality in coronavirus disease 2019 (COVID-19). · METHODS

    pubmed:42641144:ae566f049121:ae566f049121

What has been studied?

What the evidence says.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Risks and interactions

Risks, organized for scanning.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Products and regulatory status

Same ingredient. Different records.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Administration context

The practical clinical context.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Research status + gaps

What still needs better answers?

  • No publishable claim yet for: administration, contraindication, effect, interaction, regulatory, safety
  • 47 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (40), assurance_score_below_0.72 (7), current_regulatory_source_required (4), extraction_ambiguity (49), high_risk_requires_regulatory_or_two_independent_sources (7), no_direct_support (47)

These are the limits of this profile, not an exhaustive list of scientific uncertainties.

References + discovery

Open the records yourself.

  1. Advances in FGF/FGFR Signaling: Implications for Disease and Therapy. ↗

    pubmed · published 2026-09-01 · retrieved 2026-08-27T11:48:55Z

  2. Elevated circulating fibroblast growth factor 23 is associated with acute kidney injury and mortality in coronavirus disease 2019 (COVID-19). ↗

    pubmed · published 2026-01-01 · retrieved 2026-08-27T11:48:55Z

Publication history and provenance

Version 1 · Automated assessment · 2026-08-27T11:48:55Z

3f0a01de5730f0f1f2f7d1515d75a82cad606a51c891631c6ba04a9abc62e7c5